Array BioPharma to Triple Laboratory Space Over Next Four Years

Apr 04, 2001, 01:00 ET from Array BioPharma Inc.

    BOULDER, Colo., April 4 /PRNewswire/ -- Array BioPharma Inc.
 (Nasdaq:   ARRY) today announced it has entered into a long-term lease at its
 existing Boulder site.  This new lease will increase total laboratory space to
 190,000 square feet, to be phased in over the next four years.  Array's
 facilities will then accommodate 300 to 350 scientists and a total of
 400 employees.
     "State-of-the-art laboratories are critical to our strategy of becoming
 the industry's premier drug discovery company creating the next generation of
 drugs.  This additional laboratory space on our Boulder campus will enable
 Array to continue its rapid growth over the next four years," said Robert E.
 Conway, Array BioPharma's Chief Executive Officer.  "We believe the optimal
 size for a drug discovery capability includes a multidisciplinary team of
 300 to 350 scientists at a single location."
     Array's experienced scientists have created a drug discovery platform
 utilizing the latest tools and technologies including structural biology, high
 throughput screening, analytical, computational, combinatorial and medicinal
 chemistry, drug metabolism as well as process research and development.
     The new lease is for an additional 114,000 square feet of space on Array's
 Boulder campus.  This additional space, coupled with the previously announced
 expansion of Array's Longmont, Colorado, facility, will increase total
 laboratory and office space to 190,000 square feet by 2004 from its current
 50,000 square feet.  Today, Array employs 150 people in Boulder County.
 
     Array BioPharma is a drug discovery company creating new drugs through
 innovations in chemistry and structural biology.  Array's world-class
 scientific team integrates chemistry and structural biology with an
 information-based technology platform to create higher quality drug
 candidates.  Array provides drug discovery expertise to collaborators and for
 its own proprietary research.  For more information on Array BioPharma, please
 visit the company's web site at www.arraybiopharma.com.
 
     This press release contains forward-looking statements within the meaning
 of the Private Securities Litigation Reform Act of 1995 that involve
 significant risks and uncertainties, including those discussed below and
 described more fully in reports filed by Array with the Securities and
 Exchange Commission, including our final prospectus as filed on
 November 16, 2000.  Because these statements reflect our current expectations
 concerning future events, our actual results could differ materially from
 those anticipated in these forward-looking statements as a result of many
 factors.  These factors include, but are not limited to, our ability to
 achieve and maintain profitability, the extent to which the pharmaceutical and
 biotechnology industries are willing to collaborate with third parties on
 their drug discovery activities and our ability to attract and retain
 experienced scientists and management.  We are providing this information as
 of April 4, 2001.  We undertake no duty to update any forward-looking
 statements to reflect the occurrence of events or circumstances after the date
 of such statements or of anticipated or unanticipated events that alter any
 assumptions underlying such statements.
 
 

SOURCE Array BioPharma Inc.
    BOULDER, Colo., April 4 /PRNewswire/ -- Array BioPharma Inc.
 (Nasdaq:   ARRY) today announced it has entered into a long-term lease at its
 existing Boulder site.  This new lease will increase total laboratory space to
 190,000 square feet, to be phased in over the next four years.  Array's
 facilities will then accommodate 300 to 350 scientists and a total of
 400 employees.
     "State-of-the-art laboratories are critical to our strategy of becoming
 the industry's premier drug discovery company creating the next generation of
 drugs.  This additional laboratory space on our Boulder campus will enable
 Array to continue its rapid growth over the next four years," said Robert E.
 Conway, Array BioPharma's Chief Executive Officer.  "We believe the optimal
 size for a drug discovery capability includes a multidisciplinary team of
 300 to 350 scientists at a single location."
     Array's experienced scientists have created a drug discovery platform
 utilizing the latest tools and technologies including structural biology, high
 throughput screening, analytical, computational, combinatorial and medicinal
 chemistry, drug metabolism as well as process research and development.
     The new lease is for an additional 114,000 square feet of space on Array's
 Boulder campus.  This additional space, coupled with the previously announced
 expansion of Array's Longmont, Colorado, facility, will increase total
 laboratory and office space to 190,000 square feet by 2004 from its current
 50,000 square feet.  Today, Array employs 150 people in Boulder County.
 
     Array BioPharma is a drug discovery company creating new drugs through
 innovations in chemistry and structural biology.  Array's world-class
 scientific team integrates chemistry and structural biology with an
 information-based technology platform to create higher quality drug
 candidates.  Array provides drug discovery expertise to collaborators and for
 its own proprietary research.  For more information on Array BioPharma, please
 visit the company's web site at www.arraybiopharma.com.
 
     This press release contains forward-looking statements within the meaning
 of the Private Securities Litigation Reform Act of 1995 that involve
 significant risks and uncertainties, including those discussed below and
 described more fully in reports filed by Array with the Securities and
 Exchange Commission, including our final prospectus as filed on
 November 16, 2000.  Because these statements reflect our current expectations
 concerning future events, our actual results could differ materially from
 those anticipated in these forward-looking statements as a result of many
 factors.  These factors include, but are not limited to, our ability to
 achieve and maintain profitability, the extent to which the pharmaceutical and
 biotechnology industries are willing to collaborate with third parties on
 their drug discovery activities and our ability to attract and retain
 experienced scientists and management.  We are providing this information as
 of April 4, 2001.  We undertake no duty to update any forward-looking
 statements to reflect the occurrence of events or circumstances after the date
 of such statements or of anticipated or unanticipated events that alter any
 assumptions underlying such statements.
 
 SOURCE  Array BioPharma Inc.